StockData
Viatris Inc logo

Viatris Inc (VTRS) KPIs and segments

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.28−0.17 (-0.83%)

Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Viatris · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Viatris: 51 chỉ số vận hành, trong đó có New Product Launches Net Sales, Developed Markets — North America Net Sales và Developed Markets — Europe Net Sales, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Developed Markets Segment($M)2
2,2032,0262,2582,2662,1301,8992,1562,3082,3252,1732,345
Brands($M)
1,1221,0691,1891,2411,1211,0201,1011,2181,2341,1791,316
Generics($M)
1,0719521,0591,0149988721,0451,0811,0859871,004
Greater China($M)2
714680573615589556522562539544515
Brands($M)
711677570612587553520559536542513
Generics($M)
32.902.702.902.402.7022.403.302.102.60
Emerging Markets Segment($M)2
544537566572557523514535582629630
Brands($M)
441447431424416403372396395404375
Generics($M)
10188.2134146139117141137183222244
Japan, Australia and New Zealand Segment($M)2
296274307307307277336346350318373
Generics($M)
152134150147145134162155151134173
Brands($M)
144139156159161142172189198184200
Brands($M)
2,4182,3332,3462,4372,2852,1172,1662,3622,3632,3092,402
Generics($M)
1,3281,1771,3451,3111,2851,1261,3501,3761,4231,3441,424
Lipitor($M)
452462377396388388356376348389380
Norvasc($M)
200210175180183172166169162176172
EpiPen Auto-Injectors($M)
1291017915713796.773.112311680.287
Lyrica($M)
121121120127128113127130124114133
Viagra($M)
1139510410510098.588.610010610192.3
Creon($M)
97.497.498.993.191.482.490.484.678.27580.6
Celebrex($M)
76.467.166.273.37063.467.174.172.272.275.1
Zoloft($M)
71.472.666.866.861.160.258.260.658.95862
Yupelri($M)
70.762.570.671.466.658.366.662.254.555.260.5
Effexor($M)
66.76268.167.263.159.364.566.362.759.468
Influvac($M)
63.612552.712154.9
Dymista($M)
39.837.338.633.848.442.841.343.55548.245
Amitiza($M)
39.43442.440.841.633.341.138.236.93341.2
Xalabrands($M)
38.839.24238.640.737.137.141.245.642.548.2
Xanax($M)
38.134.839.534.233.932.336.538.635.434.535.1
Developed Markets Segment($M)
9377819448767381,0421,0089131,001
Greater China($M)
510497417402385362349366328
Emerging Markets Segment($M)
232247234238236208233280228
Japan, Australia and New Zealand Segment($M)
76.364.770.283.762.210310187.3135
New Product Launches Net Sales($M)
11510170.77899.579.466.885133210154
Developed Markets — North America Net Sales($M)
923883828850868870801910991986898950
Developed Markets — Europe Net Sales($M)
1,2901,3101,1901,3901,3901,2501,0901,2401,3101,3301,2701,370
Top 10 Products Concentration (% of Net Sales)(%)
41.0%38.0%40.0%38.0%37.0%38.0%36.0%33.0%34.0%
Operational (Constant-Currency) Net Sales Growth YoY(%)7
0.0%4.0%3.0%1.0%-2.0%-7.0%-9.0%-7.0%-5.0%-1.0%0.0%-2.0%
Total Revenues — Operational Growth YoY(%)
0.0%4.0%3.0%1.0%-2.0%-7.0%-9.0%-7.0%-4.0%-1.0%0.0%-2.0%
Developed Markets — Operational Net Sales Growth YoY(%)
-1.0%2.0%1.0%0.0%-5.0%-11.0%-11.0%-7.0%-5.0%-1.0%-1.0%-5.0%
Greater China — Operational Net Sales Growth YoY(%)
10.0%16.0%18.0%8.0%9.0%9.0%4.0%2.0%3.0%5.0%0.0%2.0%
JANZ — Operational Net Sales Growth YoY(%)
-5.0%0.0%-2.0%-8.0%-10.0%-14.0%-9.0%-7.0%6.0%1.0%2.0%-2.0%
Emerging Markets — Operational Net Sales Growth YoY(%)
-6.0%-2.0%0.0%8.0%7.0%-3.0%-13.0%-13.0%-14.0%-6.0%4.0%10.0%
Brands Portfolio — Operational Net Sales Growth YoY(%)
1.0%4.0%4.0%4.0%1.0%-5.0%-5.0%-8.0%-6.0%0.0%-2.0%
Generics Portfolio — Operational Net Sales Growth YoY(%)
-3.0%3.0%1.0%-3.0%-6.0%-11.0%-15.0%-5.0%-2.0%-2.0%5.0%
Foreign Currency Translation Impact on Total Revenues($M)5
2.20-49.3-162-125-76.7-61.885.248.914.598.977.2-23.5
Total Gross-to-Net Sales Deductions & Allowances($M)4
2,1252,3332,4142,2892,4612,4062,3272,4952,5982,5982,5212,578
Wholesaler Chargebacks($M)
1,0441,1621,1781,1321,2661,2611,1581,1981,2841,2831,2441,385
Commercial Rebates, Promotional & Other Allowances($M)
8799711,0499419759189711,0621,0431,0411,048952
Medicaid & Governmental Rebate Programs($M)
153157145140171179144164181205168193
Product Sales Returns Provision($M)
49.443.443.575.848.747.854.371.890.370.160.348.8
Gross Product Sales (Before Rebates & Chargebacks)($M)2
5,8606,0795,9245,9806,2085,9755,5706,0116,3366,3846,1756,404
Consolidated Net Product Sales (After GTN Deductions)($M)
3,7353,7463,5103,6913,7483,5693,2433,5153,7383,7863,6543,826
Other Revenues (Contract Manufacturing, Royalties & TSA)($M)
14.810.97.3012.912.413.111.112.713.210.79.9011.4
Gross-to-Net Sales Allowance Reserves (Ending Balance)($M)2
2,0962,1062,2002,2692,4932,4642,5172,5362,5962,5472,4912,480
Contra-Accounts Receivable Sales Allowances($M)
1,1541,2071,2231,2571,4091,4181,5031,5471,5651,5531,4831,484
Accrued Sales Allowances (Other Current Liabilities)($M)
9429009781,0111,0831,0461,014989996
Accounts Receivable Securitization & Factoring Proceeds($M)
-101-45.22960021092.20037.730.89.50
Pipeline & BD Contingent Consideration Liability (Level 3 Fair Value)($M)6
441464449372382367412556541515570215
Idorsia R&D Collaboration Liability (Selatogrel & Cenerimod Phase 3)($M)
411421392307300288270378389345345
Respiratory Delivery Platform Contingent Liability($M)
29.842.657.264.679.877.5141176150160173178
Contingent Consideration — Current Portion($M)
18.518.927.728.536.937.144.759.549.876.1
Contingent Consideration — Noncurrent Portion($M)
422445421343345330368497491139
Contingent Consideration Fair Value Remeasurement (Gain) / Loss($M)
-17.521.284.5-1.1021.1-37.7-13426.426.8-3.204.8067.8
Contingent Consideration Cash Settlements Paid($M)
6.107.607.909.907.808.5011.412.212.261.710.9229
Finished Goods Inventory (Net of Reserves)($M)3
1,9642,0012,0322,0852,0852,1852,1631,9812,2442,1192,0392,136
Raw Materials & Supplies Inventory($M)
1,3931,4581,4701,4221,5111,5471,4391,3461,2861,246687732
Work in Process (WIP) Inventory($M)
4734754254925165324945275555771,098602
Total Inventories (Footnote Disaggregation Check)($M)
3,8293,9333,9273,9994,1114,2644,0963,8544,0853,9423,8233,470
PP&E Gross — Machinery & Manufacturing Equipment($M)5
3,1753,0563,0393,0433,0453,0402,9502,8952,8622,7522,7462,775
Operating Lease Right-of-Use (ROU) Assets($M)2
251259253271266276266253268273242246
Segment Adjusted Cost of Sales — Developed Markets($M)3
9981,0361,0121,0671,0931,0059269951,0181,025976
Segment Adjusted Cost of Sales — Emerging Markets($M)
240237220249265240213231249272265
Segment Adjusted Cost of Sales — JANZ($M)
181180174177199182177199203207189
Segment Adjusted Cost of Sales — Greater China($M)
79.477.470.961.965.462.560.86065.359.261.2
Segment Adjusted SG&A Expense — Developed Markets($M)3
226230233255229250234274248292283
Segment Adjusted SG&A Expense — Emerging Markets($M)
68.974.471.183.773.678.474.369.878.17884
Segment Adjusted SG&A Expense — Greater China($M)
139127112145133125110137135131116
Segment Adjusted SG&A Expense — JANZ($M)
42.139.634.441.337.941.338.445.640.141.241.4
Segment Goodwill Carrying Value — Developed Markets($M)3
4,8814,9184,9625,0255,0055,0194,7426,7537,1436,9466,9737,107
Adjusted EBITDA (Non-GAAP)($M)3
1,1961,1881,0501,0031,1551,0799249841,2851,2081,1931,117
Adjusted EBITDA — Operational Growth YoY(%)
1.0%8.0%10.0%-1.0%-10.0%-12.0%-20.0%-12.0%-5.0%-5.0%-9.0%
EBITDA (Unadjusted)($M)
938729549543800578-2,3173409065401,034-69.7
EBITDA Adjustment — Restructuring, M&A & Special Items($M)
230347385264468285208-77.9106
Adjusted Gross Profit (Non-GAAP)($M)4
2,1762,1591,9702,1032,1042,0281,8201,9872,1932,2042,1552,208
Adjusted Gross Margin(%)
58.0%57.5%56.0%56.8%56.0%56.6%55.9%56.3%58.5%58.0%58.8%
U.S. GAAP Gross Margin(%)
38.4%38.8%32.9%31.0%36.5%37.2%35.7%34.4%38.9%38.1%41.1%
Adjusted Cost of Sales($M)
1,5741,5981,5471,6001,6561,5541,4351,5411,629
Purchase Accounting Intangible Amortization($M)
614586592683606598584674586710612
Adjusted Earnings from Operations (Non-GAAP)($M)9
1,1201,1029499091,046991813871987
Adjusted Net Earnings (Non-GAAP)($M)4
821809694659784726600656898827813
Adjusted Diluted EPS($)
0.710.690.590.570.670.620.500.540.750.690.67
Adjusted Diluted EPS — Operational Growth YoY(%)
3.0%9.0%14.0%0.0%-10.0%-12.0%-23.0%-12.0%-5.0%-5.0%-11.0%
Adjusted Weighted-Average Diluted Shares(M)
1,1611,1721,1751,1661,1721,1771,2031,2031,2001,1981,210
Acquisition & Divestiture-Related Pre-Tax Costs($M)
44.551.462.373.84053.740.77098.210587.5148
Free Cash Flow (Operating Cash Flow Less CapEx)($M)2
814329348619658167493342750320565
Free Cash Flow Excluding Transaction & Restructuring Costs($M)
728241459685866426
Transaction-Related & Restructuring Cash Costs Impacting FCF($M)
7074111343116106
Finite-Lived Intangible Assets, Net (Acquired Product Rights & Licenses)($M)8
12,40512,97113,77614,39614,94515,52215,85816,25717,08717,52718,14018,862
Finite-Lived Intangible Assets — Gross Carrying Amount($M)
33,72533,82034,31634,50734,81034,90633,90533,34934,27533,75333,83034,178
Finite-Lived Intangible Assets — Accumulated Amortization($M)
21,32120,84920,53920,11119,86519,38418,04717,09217,18816,22615,69115,316
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets($M)
675706706706778802804814892892994319
Intangible Assets Amortization Expense($M)
558572585602593583571579575597601539
Estimated Intangible Amortization — Year +1 (Next 12 Months)($M)
2,0232,0342,0692,3372,3292,3242,2512,2282,2962,2612,2552,314
Estimated Intangible Amortization — Year +2($M)
1,7701,7791,8112,1152,1072,1032,0342,1792,2432,2132,2052,235
Estimated Intangible Amortization — Year +3($M)
1,1901,1901,2131,8531,8461,8401,7931,9662,0251,9932,0062,183
Estimated Intangible Amortization — Year +4($M)
1,1831,1841,2061,2431,2401,2351,2331,7381,7811,7581,7692,102
Global Restructuring Accrual Reserve (2020 & 2026 Programs)($M)7
8760.869.80
Restructuring Reserve — Current($M)
5752.259.240.23444.713463.430.929.429.936.4
Restructuring Reserve — Noncurrent($M)
16315215511613013013112912860.957.959.2
Restructuring Reserve — Employee Severance & Benefits($M)
8760.869.80
Restructuring Reserve — Site Exit & Other Costs($M)
0000
Restructuring Charges — Employee Severance($M)
47.222.975.8
Restructuring Charges — Other Exit Costs($M)
4.904.402.10
Restructuring Cash Payments Settled($M)
20.331.45.90
Litigation & Legal Contingency Accrual — Current Portion($M)5
309303294326556541526473446453322244
Nationwide Opioid Civil Settlement Accrual (Total Carrying Value)($M)
28128128133533533533527027027015177.5
Product Liability Contingency Accrual($M)
35.635.735.567.167.366.866.870.165.965.765.364.9
Other Legal Contingencies Accrual($M)
17979.109875.708206.506.60
Generic Drug Pricing Litigation — Participating U.S. States & Territories (AG Complaint)
444444444444454544454545
Generic Drug Multidistrict Litigation (MDL) — Plaintiff States
424242424242434343444444
Gain / (Loss) on Divestitures of Businesses($M)
00-13.9-21.91.60-43.8-36.9-104-107-25970.4-240
Senior Notes Carrying Portfolio — Fair Value($M)
10,69011,11011,81011,99011,98011,81011,41011,53013,40014,22015,09015,250
Nonvested Restricted Stock Units (RSUs & PRSUs Outstanding)(M)4
29.129.731.232.933.433.834.329.129.530.632.831.1
Defined Benefit Pension & Postretirement Noncurrent Liability($M)4
399414433426479488474468491488495504
Deferred Income Tax Assets, Net($M)2
1,1731,1581,1091,061999924818753763685653693
Pacira BioSciences, Inc. (PCRX) — Total Revenues($M)6
177192177197180181169187169178167181
Pacira BioSciences, Inc. (PCRX) — Total Net Product Sales($M)4
175191177197178180168187168176166180
Pacira BioSciences, Inc. (PCRX) — EXPAREL Net Product Sales($M)
143148143156140143137148132137132144
Pacira BioSciences, Inc. (PCRX) — ZILRETTA Net Product Sales($M)
29.832.626.8332931.323.333.128.430.725.828.7
Pacira BioSciences, Inc. (PCRX) — iovera° Net Product Sales($M)
26.806.2076.505.605.106.505.705.7056
Pacira BioSciences, Inc. (PCRX) — Bupivacaine Liposome Veterinary Sales($M)
1.203.201.201.102.700.502.6001.603.202.501.10
Pacira BioSciences, Inc. (PCRX) — Royalty & Collaborative Revenue($M)
01.90001.500.801.3000.901.601.301.50
Pacira BioSciences, Inc. (PCRX) — GAAP Operating Income($M)
22.34.306.902.306.408.50224.7-14028.213.233.2
Pacira BioSciences, Inc. (PCRX) — Research & Development Expense($M)
26.730.228.137.52628.225.323.919.120.318.219.5
Pacira BioSciences, Inc. (PCRX) — Selling, General & Administrative Expense($M)
83.891.893.910291.888.686.879.674.368.17265.8
Pacira BioSciences, Inc. (PCRX) — GAAP Net Income($M)
28.54.702.901.605.40-4.804.8016-14418.9924.9
U.S. Personal Consumption Expenditures — Health Care (SAAR)($M)
3,858,6703,790,2903,699,9003,666,9903,614,8503,529,8303,464,6503,417,8303,358,2403,288,2203,244,3603,159,380
Total Revenues($M)13
3,7503,7573,5173,7043,7603,5823,2543,5283,7513,7973,6633,837
Cost of Sales($M)
2,3122,3002,3602,5562,3882,2492,0932,3132,2922,3512,1592,241
Gross Profit($M)
1,4381,4571,1571,1481,3721,3331,1611,2151,4591,4451,5041,597
Research & Development Expense($M)
232248249275250219222207198204200203
Selling, General & Administrative Expense($M)
9511,1359291,0318879299481,0471,0031,0371,0181,026
Litigation Settlements & Other Contingencies, Net($M)
11-73.2-53.53.10-55.747.673.5-112-31.5-131-76.8-148
Earnings (Loss) from Operations($M)
2626.30-79.7-193179233-2,882-180226-240204-455
Interest Expense($M)
112121120120120117116120146146138141
Earnings (Loss) Before Income Taxes($M)
128-64-247-343-7.90-217-3,097-52790.5-392205-855
Income Tax Provision (Benefit)($M)
45354.8-424-2.90120-213-55-10-4.30-65.490.7-89.4
Net Earnings (Loss) Attributable to Common Shareholders($M)
-325-119176-128-4.60-3,04294.8-326114
Diluted Earnings (Loss) Per Share($)
-0.28-0.100.15-0.110-2.550.08-0.270.09
Weighted-Average Diluted Shares Outstanding(M)
1,1491,1631,1751,1651,1731,1921,2001,1911,210
Dividends Per Share($)
0.120.120.120.120.120.120.120.120.120.120.120.12
Total Assets($M)12
34,68335,04536,83537,19337,92038,41238,47541,50144,75445,33047,34447,686
Operating Cash Flow($M)6
899382388816745220536483827379615569

6 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Viatris Inc. (formed November 16, 2020 through the combination of Mylan N.V. and Pfizer's Upjohn business) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). Pre-combination periods prior to Q4 2020 reflect Mylan N.V. historical accounting basis.
  • Commercial, Pricing & Pipeline KPIs: Standard segment and legacy brand revenue tables already displayed in the platform's segment header are not duplicated here. Instead, this sheet tracks New Product Launches Net Sales ($115.2M in Q3 2026; $323.7M in FY2025), Top-10 Product Concentration (41% in Q3 2026), North America ($923.4M) vs. Europe ($1,290.0M) net sales within Developed Markets, constant-currency operational growth & FX bridges, the full Gross-to-Net (GTN) variable consideration waterfall ($5,860.1M gross sales less $2,125.4M GTN deductions = $3,734.7M net sales in Q3 2026; $9,482.5M GTN deductions in FY2025), GTN reserves ($2,096.3M at Q3 2026), wholesaler concentration, Board-audited Global Regulatory Submissions (110 in FY2025), active development programs & customer service levels by segment, WHO prequalified essential medicines (49 in FY2025), and Idorsia Phase 3 contingent consideration ($411.0M at Q3 2026).
  • Pending Acquisition & Industry Context: On October 8, 2026, Viatris announced a definitive agreement to acquire Pacira BioSciences, Inc. (Nasdaq: PCRX) for $36.50 per share in cash ($1.65B equity value), expected to close by the end of November 2026. Standalone historical SEC XBRL product sales of Pacira (EXPAREL $142.5M, ZILRETTA $29.8M, iovera $2.0M in Q3 2026) are presented in the External section alongside monthly U.S. pharmaceutical PPI, CPI, and pharmacy retail sales series from FRED.
  • Methodology: No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated minus Standalone subtraction is performed. All figures are strictly as published (with verbatim hover quotes for text-extracted values; bound disclosures such as '>70B doses' are excluded). The only arithmetic used in derived cells is period splitting (Q4 = full year minus nine months; quarter = year-to-date minus prior year-to-date), shown in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (13)

  • Gross-to-Net Pricing Waterfall, Rebates & Channel Concentration (Key #3) › Top 3 Wholesaler Customers Concentration (% of Accounts Receivable) › McKesson Corporation Share of Consolidated Net Sales (Legacy ≥10% Threshold) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Gross-to-Net Pricing Waterfall, Rebates & Channel Concentration (Key #3) › Top 3 Wholesaler Customers Concentration (% of Accounts Receivable) › Cardinal Health Share of Consolidated Net Sales (Legacy Disclosure) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › Products in Active Development — Developed Markets › Products Pending Regulatory Approval — Developed Markets — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › Products in Active Development — Developed Markets › Products Pending Regulatory Approval — Emerging Markets — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › WHO Prequalified Essential Medicines Portfolio (Total) › Active & Pending Patents Maintained Globally — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Intangible Amortization Schedule, Restructuring, Litigation & Divestitures › Gain / (Loss) on Divestitures of Businesses › Biocon Biologics / Biocon Equity Fair Value Gain / (Loss) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Total Debt at Notional Principal Amounts — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Gross Leverage Ratio (Notional Debt / LTM Adjusted EBITDA) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Trailing Twelve Months (LTM) Adjusted EBITDA — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Consolidated Financial Statements (U.S. GAAP Context) › Operating Cash Flow › Debt Repayments — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
  • Complex Generics & Biosimilars Product Category Revenue — Discontinued after Q3 2023 following the November 2022 divestiture of the biosimilars portfolio to Biocon Biologics and commercial category realignment.
  • Annual Doses Sold & Countries Reached — Reported only as lower bounds ('>70 billion doses', '>80 billion doses', '>165 countries') in Viatris Sustainability Reports and Form 10-K.
  • Global Health Authority Inspections Count — Reported only as a lower bound ('>95 health authority inspections' in FY2025) in Viatris Sustainability Reports.

Dữ liệu cập nhật 2026-11-16.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Viatris

See a number that looks wrong?